The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.
 
Yoshiaki Nakamura
Research Funding - Taiho Pharmaceutical (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Sysmex; Takeda
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca; Sysmex
 
Taito Esaki
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Amgen Astellas BioPharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); IQVIA (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Quintiles (Inst)
 
Yoshito Komatsu
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Naoki Takahashi
No Relationships to Disclose
 
Yoshinori Kagawa
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Takeshi Kato
Honoraria - Asahi Kasei; Bayer; Chugai Pharma; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck; Nippon Kayaku; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Manabu Shiozawa
No Relationships to Disclose
 
Yoshiyuki Yamamoto
Honoraria - Asahi Kasei; Eisai; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Tadamichi Denda
Speakers' Bureau - Chugai Pharma (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
Research Funding - MSD (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Chugai Pharma; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)